Becker V. Pathological anatomy and pathogenesis of acute pancreatitis. World J Surg. 1981;5:303–13.
Article CAS PubMed Google Scholar
Liu R, Qi H, Wang J, Wang Y, Cui L, Wen Y, et al. Ulinastatin activates the renin-angiotensin system to ameliorate the pathophysiology of severe acute pancreatitis. J Gastroenterol Hepatol. 2014;29:1328–37.
Article CAS PubMed Google Scholar
Ruud TE, Aasen AO, Stadaas JO, Aune S. Effects on peritoneal proteolysis and hemodynamics of prophylactic and therapeutic infusions of high doses of aprotinin in experimental acute pancreatitis. Scand J Gastroenterol. 1986;21:1011–7.
Article CAS PubMed Google Scholar
Wisner JR Jr, Ozawa S, Renner IG. The effects of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat. Int J Pancreatol. 1989;4:383–90.
Article CAS PubMed Google Scholar
Wisner JR Jr, Renner IG, Grendell JH, Niederau C, Ferrell LD. Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rat. Pancreas. 1987;2:181–6.
Article CAS PubMed Google Scholar
Chen CC, Wang SS, Lee FY. Action of antiproteases on the inflammatory response in acute pancreatitis. JOP. 2007;8:488–94.
Sundaram S, Gikakis N, Hack CE, Niewiarowski S, Edmunds LH Jr, Koneti Rao A, et al. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost. 1996;75:76–82.
Article CAS PubMed Google Scholar
Duan HQ, Wu QL, Yao X, Fan BY, Shi HY, Zhao CX, et al. Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury. CNS Neurosci Ther. 2018;24:429–38.
Article CAS PubMed PubMed Central Google Scholar
Yates AG, Weglinski CM, Ying Y, Dunstan IK, Strekalova T, Anthony DC. Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness. J Neuroinflammation. 2022;19:8.
Article CAS PubMed PubMed Central Google Scholar
Hoque R, Sohail M, Malik A, Sarwar S, Luo Y, Shah A, et al. TLR9 and the NLRP3 inflammasome link acinar cell death with inflammation in acute pancreatitis. Gastroenterology. 2011;141:358–69.
Article CAS PubMed Google Scholar
Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. 2018;17:588–606.
Article CAS PubMed Google Scholar
Luo ZL, Sun HY, Wu XB, Cheng L, Ren JD. Epigallocatechin-3-gallate attenuates acute pancreatitis induced lung injury by targeting mitochondrial reactive oxygen species triggered NLRP3 inflammasome activation. Food Funct. 2021;12:5658–67.
Article CAS PubMed Google Scholar
Pan X, Fang X, Wang F, Li H, Niu W, Liang W, et al. Butyrate ameliorates caerulein-induced acute pancreatitis and associated intestinal injury by tissue-specific mechanisms. Br J Pharmacol. 2019;176:4446–61.
Article CAS PubMed PubMed Central Google Scholar
Ren JD, Ma J, Hou J, Xiao WJ, Jin WH, Wu J, et al. Hydrogen-rich saline inhibits NLRP3 inflammasome activation and attenuates experimental acute pancreatitis in mice. Mediators Inflamm. 2014;2014: 930894.
Article PubMed PubMed Central Google Scholar
Wang L, Wang N, Shi G, Sun S. Follistatin-like 1 ameliorates severe acute pancreatitis associated lung injury via inhibiting the activation of NLRP3 inflammasome and NF-kappaB pathway. Am J Transl Res. 2022;14:4310–20.
CAS PubMed PubMed Central Google Scholar
Li C, Wang J, Fang Y, Liu Y, Chen T, Sun H, et al. Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats. Brain Behav Immun. 2016;56:230–45.
Article CAS PubMed Google Scholar
Lin Y, Xu D, Gao F, Zheng X. Ulinastatin inhibits NLRP3-induced apoptosis in a PD cell model. Ann Transl Med. 2021;9:924.
Article CAS PubMed PubMed Central Google Scholar
Liu Z, Zhu X, Xu C, Min F, Yu G, Chen C. Ulinastatin ameliorates the malignant progression of prostate cancer cells by blocking the RhoA/ROCK/NLRP3 pathway. Drug Dev Res. 2023;84:36–44.
Article CAS PubMed Google Scholar
Qiu J, Xiao X, Gao X, Zhang Y. Ulinastatin protects against sepsis‑induced myocardial injury by inhibiting NLRP3 inflammasome activation. Mol Med Rep 2021; 24.
Schmidt J, Rattner DW, Lewandrowski K, Compton CC, Mandavilli U, Knoefel WT, et al. A better model of acute pancreatitis for evaluating therapy. Ann Surg. 1992;215:44–56.
Article CAS PubMed PubMed Central Google Scholar
Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183:787–91.
Article CAS PubMed Google Scholar
Noguchi S, Nakatsuka M, Konishi H, Kamada Y, Chekir C, Kudo T. Nafamostat mesilate suppresses NF-kappaB activation and NO overproduction in LPS-treated macrophages. Int Immunopharmacol. 2003;3:1335–44.
Article CAS PubMed Google Scholar
Xu S, Chen H, Ni H, Dai Q. Targeting HDAC6 attenuates nicotine-induced macrophage pyroptosis via NF-kappaB/NLRP3 pathway. Atherosclerosis. 2021;317:1–9.
Article CAS PubMed Google Scholar
Yang Q, Li S, Zhou Z, Fu M, Yang X, Hao K, et al. HDAC6 inhibitor Cay10603 inhibits high glucose-induced oxidative stress, inflammation and apoptosis in retinal pigment epithelial cells via regulating NF-kappaB and NLRP3 inflammasome pathway. Gen Physiol Biophys. 2020;39:169–77.
Article CAS PubMed Google Scholar
Magupalli VG, Negro R, Tian Y, Hauenstein AV, Di Caprio G, Skillern W, et al. HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation. Science 2020; 369.
Hsu CW, Shou D, Huang R, Khuc T, Dai S, Zheng W, et al. Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay. J Biomol Screen. 2016;21:643–52.
Article CAS PubMed PubMed Central Google Scholar
Chang P, Li H, Hu H, Li Y, Wang T. The Role of HDAC6 in Autophagy and NLRP3 Inflammasome. Front Immunol. 2021;12: 763831.
Article CAS PubMed PubMed Central Google Scholar
Moreno-Gonzalo O, Ramirez-Huesca M, Blas-Rus N, Cibrian D, Saiz ML, Jorge I, et al. HDAC6 controls innate immune and autophagy responses to TLR-mediated signalling by the intracellular bacteria Listeria monocytogenes. PLoS Pathog. 2017;13: e1006799.
Article PubMed PubMed Central Google Scholar
Liu L, Zhou X, Shetty S, Hou G, Wang Q, Fu J. HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury. Toxicol Appl Pharmacol. 2019;370:178–83.
Article CAS PubMed Google Scholar
Youn GS, Lee KW, Choi SY, Park J. Overexpression of HDAC6 induces pro-inflammatory responses by regulating ROS-MAPK-NF-kappaB/AP-1 signaling pathways in macrophages. Free Radic Biol Med. 2016;97:14–23.
Article CAS PubMed Google Scholar
Chen Q, Wang Y, Jiao F, Cao P, Shi C, Pei M, et al. HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway. J Cell Mol Med. 2021;25:7218–28.
Article CAS PubMed PubMed Central Google Scholar
Wang Y, Li X, Chen Q, Jiao F, Shi C, Pei M, et al. Histone Deacetylase 6 Regulates the Activation of M1 Macrophages by the Glycolytic Pathway During Acute Liver Failure. J Inflamm Res. 2021;14:1473–85.
Article PubMed PubMed Central Google Scholar
Yan S, Wei X, Jian W, Qin Y, Liu J, Zhu S, et al. Pharmacological Inhibition of HDAC6 Attenuates NLRP3 Inflammatory Response and Protects Dopaminergic Neurons in Experimental Models of Parkinson’s Disease. Front Aging Neurosci. 2020;12:78.
Article CAS PubMed PubMed Central Google Scholar
Piippo N, Korhonen E, Hytti M, Skottman H, Kinnunen K, Josifovska N, et al. Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome. Sci Rep. 2018;8:6720.
Article PubMed PubMed Central Google Scholar
Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18:601–7.
Article CAS PubMed Google Scholar
Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol. 2005;15:565–7.
Article CAS PubMed Google Scholar
Hou Q, Kan S, Wang Z, Shi J, Zeng C, Yang D, et al. Inhibition of HDAC6 With CAY10603 Ameliorates Diabetic Kidney Disease by Suppressing NLRP3 Inflammasome. Front Pharmacol. 2022;13: 938391.
Comments (0)